[1]
Nissaisorakarn P, Sharif S, Jim B. Hypertension in pregnancy: Defining blood pressure goals and the value of biomarkers for preeclampsia. Curr Cardiol Rep 2016; 18: 131.
[2]
Nakanishi S, Aoki S, Nagashima A, Seki K. Incidence and pregnancy outcomes of superimposed preeclampsia with or without proteinuria among women with chronic hypertension. Pregnancy Hypertens 2017; 7: 39-43.
[3]
Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control 2016; 9: 79-94.
[4]
Jeyabalan A. Epidemiology of preeclampsia: Impact of obesity. Nutr Rev 2013; 71(Suppl. 1): S18-25.
[5]
Al-Jameil N, Aziz Khan F, Fareed Khan M, Tabassum H. A brief overview of preeclampsia. J Clin Med Res 2014; 6(1): 1-7.
[6]
Staff AC. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertens 2011; 1(1): 28-42.
[7]
Founds S, Zeng X, Lykins D, Roberts J. Developing potential candidates of preclinical preeclampsia. Int J Mol Sci 2015; 16(11): 27208-27.
[8]
Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013; 62(4): 666-73.
[9]
Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res 2014; 8: BE01-4.
[10]
Stepan H, Hund M, Gencay M, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy 2016; 35(3): 295-305.
[11]
Acestor N, Goett J, Lee A, et al. Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings. Clin Chem Lab Med 2016; 54(1): 17-27.
[12]
Zulfikaroglu E, Islimye M, Tonguc EA, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 2011; 37(9): 1198-202.
[13]
Wellmann S, Benzing J, Fleischlin S, et al. Cardiovascular biomarkers in preeclampsia at triage. Fetal Diagn Ther 2014; 36(3): 202-7.
[14]
Santillan MK, Santillan DA, Scroggins SM, et al. Vasopressin in preeclampsia: A novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension 2014; 64(4): 852-9.
[15]
Foda AA, Abdel Aal IA. Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol 2012; 165(2): 215-8.
[16]
Łukaszyk E, Małyszko J. Copeptin: Pathophysiology and potential clinical impact. Adv Med Sci 2015; 60(2): 335-41.
[17]
Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. Eur Heart J 2009; 30(10): 1187-94.
[18]
Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: A review of a novel neurohormone. Int J Cardiol 2013; 167(5): 1750-9.
[19]
Yalta K, Sıvrı N, Yalta T, Geyik B, Aksoy Y, Yetkın E. Copeptin (C-terminal provasopressin): A promising marker of arrhythmogenesis in arrhythmia prone subjects? Int J Cardiol 2011; 148(1): 105.
[20]
Leeflang M, Cnossen J, van der Post J, Mol B, Khan K, ter Riet G. Accuracy of fibronectin tests for the prediction of pre-eclampsia: A systematic review. Eur J Obstet Gynecol Reprod Biol 2007; 133(1): 12.
[21]
Duhig KE, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia. F1000Prime Rep 2015; 7: 24.
[22]
Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis. Fetal Diagn Ther 2012; 31(3): 141-6.
[23]
Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 2014; 52(10): 1447-56.
[24]
Dobsa L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med (Zagreb) 2013; 23(2): 172-90.
[25]
Jadli A, Sharma N, Damania K, et al. Promising prognostic markers of preeclampsia: New avenues in waiting. Thromb Res 2015; 136(2): 189-95.
[26]
Struck J, Morgenthaler N, Bergmann A. Copeptin, a stablepeptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26: 2500-4.
[27]
Bankir L, Bichet D, Morgenthaler N. Vasopressin: Physiology, assessment and osmosensation. J Intern Med 2017; 282: 284-97.
[28]
Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res 2002; 139: 179-96.
[29]
Serradeil-Le Gal C, Raufaste D, Marty E, Garcia C, Maffrand J, Le Fur G. Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059. Kidney Int 1996; 50: 499-505.
[30]
Björntorp P, Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann N Y Acad Sci 1999; 892: 297-307.
[31]
Canivell S, Ponte B, Pruijm M, et al. Canivell S, Ponte B, Pruijm M, et al. Plasma copeptin is associated
with insulin resistance in a swiss population-based study. J Hypertens
2015; 33(1): 4B.05.
[32]
Enhörning S, Wang T, Nilsson P, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 18(121): 2102-8.
[33]
Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressinHorm Metab Res 1998; 30(06/07): 360-7
[34]
Grazzini E, Breton C, Derick S, et al. Vasopressin receptors in human adrenal medulla and pheochromocytoma. J Clin Endocrinol Metab 1999; 84(6): 2195-203.
[35]
Yeung EH, Liu A, Mills JL, et al. Increased levels of copeptin before clinical diagnosis of preeclampsia. Hypertension 2014; 64(6): 1362-7.
[36]
Akinlade KS, Adediji IO, Rahamon SK, Fawole AO, Tongo OO. Serum copeptin and pregnancy outcome in preeclampsia. Niger Med J 2015; 56(5): 362-8.
[37]
Cornelius D. Copeptin a new biomarker that is specific for preeclampsia? Hypertension 2014; 64(6): 1189-91.
[38]
Birdir C, Janssen K, Stanescu AD, et al. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia. Arch Gynecol Obstet 2015; 292(5): 1033-42.
[39]
Tuten A, Oncul M, Kucur M, et al. Maternal serum copeptin concentrations in early-and late-onset pre-eclampsia. Taiwan J Obstet Gynecol 2015; 54(4): 350-4.
[40]
Santillan M, Scroggins S, Nishimura T, et al. 779: First trimester urine copeptin predicts the development of preeclampsia. Am J Obstet Gynecol 2016; 214(1): S407.
[41]
Yeşil A, Kanawati A, Helvacıoğlu Ç, Kaya C, Özgün ÇG, Cengiz Hs. Identification of patients at risk for preeclampsia with the use of uterine artery Doppler velocimetry and copeptin. J Matern Fetal Neonatal Med 2016; 30(22): 2763-8.
[42]
Jadli A, Ghosh K, Satoskar P, Damania K, Bansal V, Shetty S. Combination of copeptin, placental growth factor and total annexin V microparticles for prediction of preeclampsia at 10e14 weeks of gestation. Placenta 2017; 58: 67-73.
[43]
Scroggins SM, Santillan DA, Lund JM, et al. Elevated vasopressin in pregnant mice induces t helper subset alterations consistent with human preeclampsia. Clin Sci 2018; 132(3): 419-36.
75
4